Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL
Zelenetz, A. D. Jurczak, W. Ribrag, V. Linton, Kim M Collins, G. P. Lopez-Jimenez, J. Reddy, N. Mengarelli, A. Phillips, T. J. Musuraca, G.
Zelenetz, A. D.
Jurczak, W.
Ribrag, V.
Linton, Kim M
Collins, G. P.
Lopez-Jimenez, J.
Reddy, N.
Mengarelli, A.
Phillips, T. J.
Musuraca, G.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Zelenetz AD, Jurczak W, Ribrag V, Linton K, Collins GP, Lopez-Jimenez J, et al. Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301972.